/PRNewswire/ Dr. Morris C. Laster ("Dr. Laster"), who, together with other proxy participants, beneficially owns 6,006,000 shares of common stock, par value.
/PRNewswire/ Dr. Morris C. Laster ("Dr. Laster"), who, together with other proxy participants, beneficially owns 6,006,000 shares of common stock, par value.
Company’s Director Nominees are Highly Qualified and Experienced with Track Records of Guiding Early-Stage Life Science Companies Executing Strategy to.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Scopus BioPharma Announces Appointment of Additional Directors
December 29, 2020 GMT
(PRNewsfoto/Scopus BioPharma Inc.)
NEW YORK, Dec. 29, 2020 /PRNewswire/ Scopus BioPharma Inc. (Nasdaq: SCPS) today announced the appointment of additional members to its Board of Directors. Scopus is a biopharmaceutical company whose lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers.
Joshua R. Lamstein, Chairman of Scopus BioPharma, stated, “We are delighted to be in a position to attract prominent industry leaders to our Board. Our new directors are well-recognized for their leadership and accomplishments in the biopharmaceutical, biotechnology and pharmaceutical industries, as well as in public capital markets and corporate governance.”